Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)Seeking Alpha • 03/28/25
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply ChainInvestors Business Daily • 03/27/25
Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted ReturnsSeeking Alpha • 03/26/25
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancerPRNewsWire • 03/26/25
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)PRNewsWire • 03/26/25
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanZacks Investment Research • 03/24/25
2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth PortfolioSeeking Alpha • 03/22/25
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four YearsBusiness Wire • 03/21/25
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's diseasePRNewsWire • 03/20/25
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer BreakthroughBenzinga • 03/20/25
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025PRNewsWire • 03/20/25
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's DiseaseZacks Investment Research • 03/19/25
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designationPRNewsWire • 03/18/25